{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T09:14:05Z","timestamp":1776244445555,"version":"3.50.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10072-026-08952-2","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T03:11:01Z","timestamp":1773457861000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early anti-C5 therapy in NMOSD: rationale and clinical evidence"],"prefix":"10.1007","volume":"47","author":[{"given":"Haruka","family":"Kido","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0022-9529","authenticated-orcid":false,"given":"Satoru","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikiaki","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"issue":"7","key":"8952_CR1","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K et al (2019) Eculizumab in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder. N Engl J Med 381(7):614\u2013625","journal-title":"N Engl J Med"},{"issue":"3","key":"8952_CR2","first-page":"215","volume":"22","author":"T Yamamura","year":"2023","unstructured":"Yamamura T, Kleiter I, Fujihara K et al (2023) Ravulizumab for aquaporin-4 IgG\u2013seropositive neuromyelitis optica spectrum disorder: A randomized controlled trial. Lancet Neurol 22(3):215\u2013226","journal-title":"Lancet Neurol"},{"key":"8952_CR3","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12974-018-1167-8","volume":"15","author":"BC Kieseier","year":"2018","unstructured":"Kieseier BC et al (2018) Complement activation in neuromyelitis optica: Biomarker evidence and therapeutic implications. J Neuroinflammation 15:138","journal-title":"J Neuroinflammation"},{"key":"8952_CR4","first-page":"104789","volume":"80","author":"S Watanabe","year":"2024","unstructured":"Watanabe S et al (2024) Delayed initiation of eculizumab in subacute attacks of AQP4-IgG-positive NMOSD: A case series. Mult Scler Relat Disord 80:104789","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"8952_CR5","first-page":"e1472","volume":"11","author":"A San-Galli","year":"2024","unstructured":"San-Galli A et al (2024) Rescue eculizumab therapy in severe AQP4-positive NMOSD attacks unresponsive to standard treatment: Two case reports. Neurol Neuroimmunol Neuroinflamm 11(2):e1472","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"8952_CR6","first-page":"578058","volume":"383","author":"A Salih","year":"2023","unstructured":"Salih A et al (2023) Real-world experience of ravulizumab in neuromyelitis optica spectrum disorder: A case series from the Middle East. J Neuroimmunol 383:578058","journal-title":"J Neuroimmunol"},{"issue":"1","key":"8952_CR7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12883-024-03616-0","volume":"24","author":"K Saito","year":"2024","unstructured":"Saito K et al (2024) Early use of ravulizumab in acute thoracic myelitis due to AQP4-positive NMOSD: A case report. BMC Neurol 24(1):115","journal-title":"BMC Neurol"},{"key":"8952_CR8","first-page":"175628642211114","volume":"15","author":"Y Takeshita","year":"2022","unstructured":"Takeshita Y et al (2022) CH50 as a pharmacodynamic marker of eculizumab efficacy in NMOSD: A case series. Ther Adv Neurol Disord 15:17562864221111432","journal-title":"Ther Adv Neurol Disord"},{"issue":"27","key":"8952_CR9","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","volume":"66","author":"LA McNamara","year":"2017","unstructured":"McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR (2017) High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite vaccination. MMWR Morb Mortal Wkly Rep 66(27):734\u2013737","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-08952-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-08952-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-08952-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T08:39:08Z","timestamp":1776242348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-08952-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["8952"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-08952-2","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"I hereby confirm that all authors have agreed to the contents of the submission. There are no disclosures, competing interests or funding. There was full compliance with ethical standards including informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}}],"article-number":"345"}}